Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies
Could Be Worth $900m
News of the deal emerged as the UK firm's shares skyrocketed after its SPEAR T-cell platform delivered responses in four solid tumor types.
You may also be interested in...
Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.